32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cost-effectiveness analysis and prevention effects of ultra-orphan drugs for rare diseases: an in silico model applied to Cryopyrin Associated Periodic Syndromes (CAPS)

      abstract
      1 , 2 , 1 , 1 , 2 , 1 , 3 , 4 , , 5 , 4
      Pediatric Rheumatology Online Journal
      BioMed Central
      8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
      30 September-3 October 2015

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives This three-year, international, multicentre, longitudinal, observational, cost-effectiveness study named RaDiCEA (RareDisease &Cost-EffectivenessAnalysis) will assess the economic evaluation (cost of illness - COI and cost-effectiveness analysis - CEA) of innovative therapies (i.e., anti IL-1 agents), quality of life (QoL) and effects of the prevention of otherwise irreversible central nervous system, eye, ear, kidney, and cartilage damages of different treatment strategies for cryopyrin-associated periodic syndromes (CAPS) of adults and children. Methods A virtual time-cohort approach and a Markov model simulating health states corresponding to different CAPS severity will be developed to assess the cost-effectiveness of two different treatment strategies: i.e., either anti IL-1 agents or other than anti IL-1. Due to the lack of a CAPS-specific severity index/damage score, a linear combination of existing indexes and damage scores will be used to rank patient's health status with respect to damages involving specific organs and systems. Coefficients of the resulting function will be assigned following both a top-down (Delphi) and an interim-ex post-bottom-up approach (principal component analysis) considering covariances of all the variables adopted to describe the disease evolution or response to therapies. The model uses relevant economic measures to quantify resource utilization for patients' care in the National Health Systems' perspectives and a broader societal perspective to take into account direct nonmedical costs and indirect costs, in addition to direct costs. QoL will be evaluated using EQ-5D questionnaires. To assess how the model reacts to changes in singular and multiple disease parameters, univariate and probabilistic sensitivity analyses will be performed. Expected results The RaDiCEA project will assess the long-term effectiveness of different potentially life-long treatment strategies and COI, while exploring the feasibility of a new CEA model to be generated from a rare disease (CAPS) observational study. The economic outcomes will be given as the number of years spent in each health state, the related yearly costs and QoL. Conclusions The importance and novelty of the model is twofold: i) in its application, adopting the cost-effectiveness approach for assessing the impact of CAPS therapies, and ii) in the methods, extending the analyses of the impact of CAPS therapies in reducing the speed of disease progression.

          Related collections

          Author and article information

          Conference
          Pediatr Rheumatol Online J
          Pediatr Rheumatol Online J
          Pediatric Rheumatology Online Journal
          BioMed Central
          1546-0096
          2015
          28 September 2015
          : 13
          : Suppl 1
          : P185
          Affiliations
          [1 ]Scuola Superiore Sant'Anna, Institute of Management, Pisa, Italy
          [2 ]Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Giannina Gaslini, Unità di Farmacologia Clinica e Sperimentazioni Cliniche, Direzione Scientifica, Genova, Italy
          [3 ]University Medical Center Utrecht, Utrecht, Netherlands
          [4 ]Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Giannina Gaslini, Pediatria II, Reumatologia, Genova, Italy
          [5 ]Assistance Publique-Hopitaux de Paris Hopital Necker,, Paediatric Immunology, Haematology and Rheumatology Unit, Paris, France
          Article
          1546-0096-13-S1-P185
          10.1186/1546-0096-13-S1-P185
          4599848
          fe84f767-623c-4976-9a07-22023ee7893d
          Copyright © 2015 Trieste et al.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

          8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
          Dresden, Germany
          30 September-3 October 2015
          History
          Categories
          Poster Presentation

          Pediatrics
          Pediatrics

          Comments

          Comment on this article